

Dr. Shaima Sultana Memon et. al

InVitro Activity of Colistin and Other Agents against Multidrug Resistant Pseudomonas Aeurginosa

InVitro Activity of Colistin and Other Agents against Multidrug Resistant Pseudomonas Aeurginosa

Dr. Shaima Sultana Memon¹, Dr. Soha Haque², Dr. Zafar Iqbal³, *Dr. Lubna Farooq⁴, Dr.Faisal Ali Baloch⁵, Muneeza Lodhi⁶

¹Assistant Professor, Dept. of Pathology, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan

²Lecturer, Dept. of Pharmacology, Ziauddin Medical College, Ziauddin University, Karachi, Pakistan

³Assistant Professor & Head, Dept. of Preventive and Community Dentistry, Bhattai Dental and Medical College, Mirpurkhas, Pakistan

⁴Assistant Professor, Dept. of Pharmacology, Baqai Dental College, Baqai Medical University, Karachi, Pakistan

⁵Assistant Professor, Dept. of Dental Materials, Baqai Dental College, Baqai Medical University, Karachi, Pakistan

⁶Assistant professor, Faculty of Pharmacy, Ziauddin University, Karachi, Pakistan

ABSTRACT

Objective

The current research sought to evaluate the in vitro activity of Colistin and other agents against multi-drug resistant Pseudomonas aeruginosa isolates.

Methodology

This in vitro cross-sectional research was carried out October and December 2018 after receiving ethical approval. Pus, wound swabs, blood, tracheal aspirates, and urine samples were regularly collected and obtained from in-patient and out-patient clinics. All samples were given to the department of microbiology at Ziauddin University Hospital's North Nazimabad campus for culture and sensitivity testing. All samples were analyzed in accordance with the CLSI Guidelines 2018.

Results

Of the 276 Pseudomonas aeruginosa isolates, the majority were from pus (34.2%). MDR Pseudomonas aeruginosa were present in 152 (55%). Female isolates were more resistant than male isolates. Antibiotic susceptibility tests revealed that 24% and 20% of P. aeruginosa isolates,

Dr. Shaima Sultana Memon et. al

InVitro Activity of Colistin and Other Agents against Multidrug Resistant Pseudomonas Aeruginosa

respectively, were susceptible to ceftazidime and Imipenem. While Colistin was effective against all P. aeruginosa isolates (p- 0.001).

Conclusion

Colistin outperformed Imipenem and Ceftazidime against MDR P. Aeruginosa isolates. Colistin has thus emerged as an effective and significant substitute against MDR isolates of P. Aeruginosa, it could be used when no other options are available or the disease is severely detrimental.

Keywords:Pseudomonas aeruginosa, Colistin, Ceftazadine, Imipenem, Antibacterial resistance

Tob Regul Sci.™ 2023;9(1): 205-214

DOI: doi.org/10.18001/TRS.9.1.13

Address for correspondence:

Dr. Lubna Jahanzeb

Assistant Professor, Dept. of Pharmacology, Baqai Dental College, Baqai Medical University, Karachi, Pakistan

Email: jlubna85@gmail.com

INTRODUCTION

The development of antibacterial drugs represents a turning point in modern science(1). Antibacterial drugs are the most commonly used and effective agents in medicine for treating a wide variety of diseases caused by bacterial infections (2). Every day, antibiotic agents save millions of lives all over the world. However, there is a major global threat: the rise of antibacterial resistance (1). The increased use, and repeatedly misuse, of antibacterial drugs has resulted in the occurrence of bacteria that no longer respond to therapeutic interventions (3).

Pseudomonas aeruginosa has remained one of the most concerning pathogenic organisms associated with antibiotic resistance. P. aeruginosa causes the blood infections, respiratory infections, skin conditions, urinary tract infections, and surgical site infections (4, 5). The occurrence of significant innate and acquired resistance factors in this pathogen frequently leads in poor outcome measures. Pseudomonas aeruginosa has been categorized as an ESKAPE organism and is associated with a broad range of acquired infection(6).

Multi - drug resistant bacteria are those that are resistant to at least one antibiotic in three or more different categories. The rise in multi-drug resistance Pseudomonas aeruginosa (MDRPA) bacterial infection in past few years has hampered the choice of a suitable antibiotic therapy, resulting in a spike in rates of mortality and morbidity in patients with such an infection(7).

Resistance to commonly used antimicrobials, such as antipseudomonal beta-lactams or quinolones, has resulted in the adoption of alternative medicines(8, 9).

Consequently, there are limited treatment options available due to the development of these pathogenic organisms' resistance processes, primarily as a result of the indiscriminate use of antibiotics, inability to follow therapeutic regimens, variability in dosage administered, and accessibility of over-the-counter medications (10).

Recently, due to the shortage of conventional antibiotics with activity against Gram-negative bacteria, Colistin has been reevaluated to treat a variety of infections caused by MDR strains. Colistin resistance is incredibly low; however, much work remains to be done before it can be used in clinical settings (11). As a result, the purpose of this study was to assess the in vitro activity of Colistin and other agents against multi-drug resistant isolates of *P. aeruginosa*.

MATERIALS AND METHODS

It was a quasi-experimental study performed in a laboratory setting. The study was carried out at Microbiology lab of Ziauddin Hospital, North Campus, and Karachi. The study was approved by the ethics committee of the University. Between October and December 2018, 276 pus, ear swab, blood, sputum, tracheal aspiration and urine specimens were processed for culture and sensitivity testing in accordance with established guidelines.

Samples were cultured with normal culture media on MacConkey agar (Oxoid) and Blood agar (Oxoid). The plates were kept at 37° Celsius for 24 hours. All gram negative, catalase, and oxidase positive colonies were identified to the species level using standard microbiological procedures.

Antibiotic susceptibility was determined using Kirby Bauer's disc diffusion method. Using this method, a bacterial inoculum surface was created on a 150 mm Mueller Hinton Agar plate (Oxoid UK). Colistin, Imipenem and Ceftazidime antibiotic discs were placed on an agar plate. Before determining the results, the plates were incubated at 35°C for 16-24 hours. CLSI (2018) recommended that the zones of growth inhibition around each antibiotic disc be quantified and labelled as sensitive or resistant(12).

Determination of MIC

The MICs of the strains for both antimicrobial were determined using 96-well microtitre plates and the broth microdilution method. The bacterial inoculum was prepared in the amount of 0.5 McFarland (approximately 1.5 x 10⁸ CFU/ml). To achieve the final inoculum (approx. 1.5 x 10⁶ CFU/ml), the inoculum was diluted 1:100 by cation-adjusted MuellerHinton broth (CA-MHB), and 10 ul of this was added to 100 µl of CA-MHB(13, 14). The plates were incubated for 18 hours at 35±2°C. After incubation, the presence or absence of turbidity in wells was noted and interpreted using CLSI supplement 2013 MIC criteria.

Statistical Analysis

The Statistical Package for Social Sciences (SPSS) version 21 was used to analyse the data. For numerical variables, descriptive analyses were expressed as Mean with Standard Deviation. For categorical variables, frequencies and percentages were determined. The Chi square test was used to evaluate the relationship between drug sensitivity and resistance patterns, with a p value less than 0.05 considered significant.

RESULTS

On the basis of identification method, two hundred and seventy six strains of P. Aeruginosa were isolated from 1900 specimen. Out of which 55% were MDR P.Aeruginosa and 45% were only P.Aeruginosa. MDR P.Aeruginosa frequency was slight more in females 54% as compared to male 46%. P-value of 0.52 was statistically non-significant.

Table-I: Total samples of Pseudomonas Aeruginosa			
Total Sample	MDR	Non- MDR	p-value
276	152 (55%)	124 (45%)	0.52
Male 133 (46%)	70 (46%)	63 (51%)	
Female 143 (54%)	82 (54%)	61 (49%)	

As shown in Table-II, the majority of the isolates (34.2%) were obtained from pus, followed by tracheal aspiration (20.6%), urine (18.6%), and ear swab (2.1%). The P - value was 0.024, indicating statistical significance.

Table-II: Frequency of MDR Pseudomonas Aerigonsa in specimen.			
Source	MDR	Non- MDR	

	152 (55%)	124 (45%)	p-value
Urine	28 (18.6%)	38 (30.6%)	0.024
Blood	16 (10.5%)	13 (10.5%)	
Ear Swab	3 (2.1%)	6 (4.8%)	
Pus	52 (34.2%)	19 (15.3%)	
Tracheal asp	31 (20.6%)	26 (20.9%)	
Sputum	22 (14.4%)	22 (17.7%)	

As demonstrated in Table-III, the majority of MDR P.Aerigonsastrains were isolated from the outpatient department, followed by surgical ward, ICU, medicine ward and Gynecology ward.

Table-III: Percentage of MDR isolates in different Departments.			
Department	MDR 152	Non- MDR 124	p-value
Gynecology ward	5 (3%)	0 (0%)	0.29
Medicine ward	18 (11.8%)	12 (10.1%)	
Surgery ward	41 (27.1%)	47 (38%)	
ICU	25 (16.5%)	27 (21.5%)	
Outpatient Department	63 (41.2%)	38 (30.4%)	




Figure 1: Antibiotic susceptibility of MDR P. Aeruginosa

Imipenem (80%)and Ceftazidine (76%) showed more resistant pattern against MDR Pseudomonas Aerigonsathan Colistin which showed only 1% resistant pattern as shown in Figure 1.

Drug	Sensitive	Resistant	p-value
Imipenem	20%	80%	0.0001
Ceftazadine	24%	76%	
Colistin	99%	1%	

The sensitive pattern of the three drugs differed significantly (p-0.0001) against MDR Pseudomonas Aeruginosa, with Colistin being the most susceptible agent. (Table-IV)

DISCUSSION

Multidrug-resistant P. aeruginosa is a serious global problem that affects many people. In an era of emerging resistant strains, particularly among MDR bacteria, there is renewed interest in the use of new antimicrobial options (15).

In the present study, Multi-Drug Resistant strains of P. aeruginosa were discovered to be more widespread in the female population (54%), compared to 46% in the male population. The

findings are comparable to those of a study performed in Nepal, which found that MDR *P. aeruginosa* strains were (64%) higher in females than (31%) relatively lower in males(16).

Previously, clinical research findings evaluated the efficacy of various antimicrobial treatments in patients with MDR bacterial infectious diseases(17). The most effective antibiotics for treating *Pseudomonas aeruginosa* are beta lactams (Imipenem, meropenem, and doripenem). The ineffectiveness of beta-lactams is caused by the actions of beta-lactamases, which break the amide bond of the -lactam ring, impeding infection treatment and leading to poor clinical outcomes (18).

A study by D'Souza et al. found that the majority of the *Pseudomonas Aeruginosa* isolates were resistant to Ceftazidime(19). Hence, Colistin might be an efficient solution, as a last resort for the treatment of multi-drug-resistant *Pseudomonas aeruginosa*, therefore, its antimicrobial activity should be tested on an international and domestic scale to ensure its useful application(20, 21).

In the current study, multi-drug resistant *P. aeruginosa* isolates obtained from inpatient and outpatient were susceptible to 2µg/ml Colistin. These findings are consistent with the findings of the CANWARD research, which found that the MIC values of 76 MDR *Pseudomonas Aeruginosa* toward Colistin were ≤ 2 µg/ml(22). In another research by Hsueh et al. in Taiwan found that Colistin at a concentration of 2 µg/ml suppressed 90% of isolates that were susceptible to Colistin(23).

In addition Memer et al. executed a comparable study to determine the role of Colistin in the treatment of multidrug resistant *Pseudomonas* and discovered that Colistin is more efficacious than beta lactam drugs(24).

In a Saudi Arabian study, the susceptibility of 33 MDR *P. aeruginosa* isolates to Colistin and carbapenems was determined using the E test and the CLSI breakpoint recommendation. Their findings, however, demonstrate that Colistin had significant activity against 93.9% of the strains, a result that is validated by our data, most likely because Saudi Arabia expresses the same activity to Pakistan in terms of living(25).

Tam et al. (2010) discovered that Colistin was effective against 95% of MDR-PA isolates with 1.5 and 2 µg/ml. One out of the 19 strains isolated in this research, 5% was Colistin resistant with 3 µg/ml(26).

The antimicrobial sensitivity screening of *P. aeruginosa* isolates from tracheal secretions conducted in a research by Yayan also demonstrated that Colistin was the only antibacterial agent that displayed no resistance over the years, despite the reality that the number of *P. aeruginosa* isolates evaluated for Colistin was quite low. Little recent evidence on the susceptibility of

Dr. Shaima Sultana Memon et. al

InVitro Activity of Colistin and Other Agents against Multidrug Resistant *Pseudomonas Aeruginosa*

Gram-negative bacteria to Colistin are accessible, in part because Colistin clinical isolates remains difficult and in part because Colistin use is not widely spread.

CONCLUSION

In conclusion, Colistin demonstrated encouraging in vitro experiments against MDR strains in our geographical area. These findings point to Colistin-based treatment for patients with MDR infections. However, further research on a larger collection of drug-resistant strains is required to back up these findings in the near future.

Financial Support: This research was supported by Ziauddin University

Conflict of Interest: Authors report that they have no conflict of interest. The authors alone are responsible for the content and writing of this article.

Ethical approval: ERC was provided by Ziauddin University in accordance with the declaration of Helsinki.

Informed consent: Informed consent was obtained

REFERENCES

1. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. *Pharmacy and therapeutics*. 2015;40(4):277.
2. Principi N, Silvestri E, Esposito S. Advantages and limitations of bacteriophages for the treatment of bacterial infections. *Frontiers in pharmacology*. 2019;10:513.
3. Castro-Sánchez E, Moore LS, Husson F, Holmes AH. What are the factors driving antimicrobial resistance? Perspectives from a public event in London, England. *BMC infectious diseases*. 2016;16(1):1-5.
4. Breidenstein EB, de la Fuente-Núñez C, Hancock RE. *Pseudomonas aeruginosa*: all roads lead to resistance. *Trends in microbiology*. 2011;19(8):419-26.
5. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant *Pseudomonas aeruginosa* infections. *Clinical microbiology reviews*. 2019;32(4):e00031-19.
6. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. *Pseudomonas aeruginosa*: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. *Signal Transduction and Targeted Therapy*. 2022;7(1):1-27.
7. Pachori P, Gothwal R, Gandhi P. Emergence of antibiotic resistance *Pseudomonas aeruginosa* in intensive care unit; a critical review. *Genes & diseases*. 2019;6(2):109-19.
8. Martis N, Leroy S, Blanc V. Colistin in multi-drug resistant *Pseudomonas aeruginosa* blood-stream infections: a narrative review for the clinician. *Journal of Infection*. 2014;69(1):1-12.

9. Nakamura I, Yamaguchi T, Tsukimori A, Sato A, Fukushima S, Matsumoto T. New options of antibiotic combination therapy for multidrug-resistant *Pseudomonas aeruginosa*. *European Journal of Clinical Microbiology & Infectious Diseases*. 2015;34(1):83-7.
10. Bashir MF, Qazi JI, Ahmad N, Riaz S. Diversity of urinary tract pathogens and drug resistant isolates of *Escherichia coli* in different age and gender groups of Pakistanis. *Tropical journal of pharmaceutical research*. 2008;7(3):1025-31.
11. Gupta S, Govil D, Kakar PN, Prakash O, Arora D, Das S, et al. Colistin and polymyxin B: a re-emergence. *Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine*. 2009;13(2):49.
12. Moini AS, Soltani B, Ardakani AT, Moravveji A, Erami M, Rezaei MH, et al. Multidrug-resistant *Escherichia coli* and *Klebsiella pneumoniae* isolated from patients in Kashan, Iran. *Jundishapur journal of microbiology*. 2015;8(10).
13. Abdulkadir I, Nasir I, Sofowora A, Yahaya F, Ahmad A, Hassan I. Phytochemical screening and antimicrobial activities of ethanolic extracts of *Moringa oleifera* Lam on isolates of some pathogens. *Journal of applied pharmacy*. 2015;7(4):2-7.
14. Dhamane S, Patil S, Kulkarni A, Potnis V. Evaluation of antimicrobial activity of ethanolic extract of *Murraya koenigii* against *S. mutans*. *Journal of Pharmacognosy and Phytochemistry*. 2019;8(4):1223-8.
15. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. *Clinical microbiology reviews*. 2008;21(3):449-65.
16. Kattel HP, Mishra SK, Acharya J, Sigdel MR, Prasad N, Shah ASS, et al. Antibiotic sensitivity profile of different uropathogens in a tertiary care center in Nepal. *Journal of Nepal Association of Medical Laboratory Science*. 2012;11(1):19-33.
17. Kagami K, Ishiguro N, Yamada T, Niinuma Y, Iwasaki S, Taki K, et al. Efficacy and safety of colistin for the treatment of infections caused by multidrug-resistant gram-negative bacilli. *Journal of Infection and Chemotherapy*. 2021;27(3):473-9.
18. Lee AS, De Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, Peschel A, et al. Methicillin-resistant *Staphylococcus aureus*. *Nature reviews Disease primers*. 2018;4(1):1-23.
19. D'Souza BB, Padmaraj SR, Rekha PD, Tellis RC, Prabhu S, Pothen P. In vitro synergistic activity of colistin and ceftazidime or ciprofloxacin against multidrug-resistant clinical strains of *Pseudomonas aeruginosa*. *Microbial Drug Resistance*. 2014;20(6):550-4.
20. Rossitto M, Fiscarelli EV, Rosati P. Challenges and promises for planning future clinical research into bacteriophage therapy against *Pseudomonas aeruginosa* in cystic fibrosis. An argumentative review. *Frontiers in microbiology*. 2018;9:775.
21. Di X, Wang R, Liu B, Zhang X, Ni W, Wang J, et al. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant *Pseudomonas aeruginosa*. *The Journal of antibiotics*. 2015;68(9):551-5.

22. Walkty A, DeCorby M, Nichol K, Karlowsky J, Hoban D, Zhanel G. In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. *Antimicrobial agents and chemotherapy*. 2009;53(11):4924-6.
23. Hsueh S-C, Lee Y-J, Huang Y-T, Liao C-H, Tsuji M, Hsueh P-R. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, and *Stenotrophomonas maltophilia*, all associated with bloodstream infections in Taiwan. *Journal of Antimicrobial Chemotherapy*. 2019;74(2):380-6.
24. Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. *Chest*. 2000;117(4):1017-22.
25. Alfouzan W, Dhar R, Nicolau DP. In vitro activity of newer and conventional antimicrobial agents, including fosfomycin and colistin, against selected Gram-negative bacilli in Kuwait. *Pathogens*. 2018;7(3):75.
26. Tam VH, Chang K-T, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, et al. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of *Pseudomonas aeruginosa*. *Antimicrobial agents and chemotherapy*. 2010;54(3):1160-4.